UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 OF THE
SECURITIES EXCHANGE ACT OF 1934
For the Month of October 2023
Commission file number 001- 41291
Meihua International Medical Technologies Co., Ltd.
(Translation of registrant’s name into English)
88 Tongda Road, Touqiao Town
Guangling District, Yangzhou, 225000
People’s Republic of China
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
Form 20-F ☒ Form 40-F ☐
Explanatory Note
Meihua International Medical Technologies Co., Ltd. (the “Company”) is furnishing its unaudited financial statements for the six months ended June 30, 2023 and incorporating such financial statements into the Company’s registration statement referenced below. The financial statements and notes are attached as Exhibit 99.1 to this report. Management’s Discussion and Analysis of Financial Condition and Results of Operations for the six months ended June 30, 2023 is attached as Exhibit 99.2 to this report.
This Form 6-K is hereby incorporated by reference into the registration statement on Form F-3 of the Company (File Number 333-274194), as amended, and into the prospectus contained within the foregoing registration statement, to the extent not superseded by documents or reports subsequently filed or furnished by the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended.
EXHIBIT INDEX
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Meihua International Medical Technologies Co., Ltd. |
Dated: October 2, 2023 | | |
| By: | /s/ Xin Wang |
| Name: | Xin Wang |
| Title: | Chief Executive Officer |
| | (Principal Executive Officer) |